Checking the pancreas in people with fatty liver and metabolic syndrome
Checks pancreatic fat and pancreas function in adults with fatty liver and metabolic syndrome.
Plain-language title generated from the registry record
Registry title: Fatty Liver and Pancreatic Steatosis
Key facts
- Where
- Ciudad Autonoma de Buenos Aires, ArgentinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06757348, who can take part
Where in Argentina
- Hospital de Clinicas Jose de San MartinCiudad Autonoma de Buenos Aires, ArgentinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Maria Marta Piskorz
- Trial code
- NCT06757348
- Record updated
- 6 August 2025
- Original description
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.Read full original descriptionShow less
Association Between Fatty Liver and Pancreatic Steatosis in Patients With Metabolic Syndrome
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.
Participants with fatty liver and metabolic syndrome will undergo fecal elastase measurement and endoscopic ultrasound (EUS).
Inclusion: Patients over 18 years old with a diagnosis of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Exclusion: Chronic hepatitis B or C infection; Autoimmune liver diseases: autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis; Wilson's disease; Celiac disease; Uncontrolled thyroid disease; Active or chronic infectious disease; Active cancer or ongoing treatment; Chronic renal insufficiency; - Alcohol consumption >20 g/day in women, >30 g/day in men; Hereditary hemochromatosis; Alpha-1 antitrypsin deficiency; Pregnancy/lactation; Insufficient data; Patients who do not complete follow-up.